Despite his tax woes, Shkreli is offering $10 million to Kanye West for sole possession of the singer's new album.» Read More
One of the most valuable Silicon Valley startups is under fire, according to the Wall Street Journal.
Voter initiatives in California and Ohio to control prescription med prices have ramifications for the presidential contest.
Turing Pharmaceuticals is not saying if it's actually cutting the exorbitant price of Daraprim as its CEO has promised.
London's Royal Free Hospital says Pauline Cafferkey, who is being treated for complications resulting from Ebola, is now critically ill.
The same drug development news that's hurting Eli Lilly shares might be good for Amgen and Sanofi-Regeneron.
A strong majority say the Affordable Care Act will play an important role in their vote.
Johnson & Johnson has begun clinical trials for an Ebola vaccine in Sierra Leone.
Stock markets are fixated on Fed policy, but two experts believe investors should forget the U.S. central bank for now.
A Scottish nurse who contracted the Ebola virus in Sierra Leone last year is back in hospital for more treatment.
Delhi's dengue outbreak has seen more than 9,000 registered cases and 30 deaths, the highest numbers since 2006, the NYT reports.
Countries that spend much less on health care tend to see better overall health outcomes than the U.S.
CareDx warns it won't be able to sell its transplant rejection test if a proposed Medicare reimbursement cut goes through.
Drugmaker Roche said its experimental medicine for multiple sclerosis performed better in a late-stage clinical trial than a commonly used therapy.
Childhood obesity is a major epidemic and the government can save billions by helping to fight it in this way, says Curt Ellis.
Indonesia's president said on Thursday that he had asked Singapore, Russia, Malaysia and Japan for help to put out forest fires.
As a joint federal-state program serving the poor, Medicaid stands on narrower, shakier ground. That's especially true in the GOP presidential race.
Express Scripts, the largest pharmacy benefits manager in the U.S., says it's got a plan to fight drug price increases: Refuse to pay.
Overall, people spent more than two hours on the average doctor's visit, which means they spent two hours not doing work.
Feeling pretty good about these stocks
The nation's largest pharmacy benefit manager plans to control costs from new cholesterol drugs through discounts and restricting use.
Get the best of CNBC in your inbox